Low Renalase Levels in Newly Diagnosed CML: Dysregulation Sensitive to Modulation by Tyrosine Kinase Inhibitors
Jelena Milenkovic, Dijana Stojanovic, Sanja Velickovic, Branka Djordjevic, Goran Marjanovic, Maja Milojkovic · 2024
Read Low Renalase Levels in Newly Diagnosed CML: Dysregulation Sensitive to Modulation by Tyrosine Kinase Inhibitors by Jelena Milenkovic, Dijana Stojanovic, Sanja Velickovic, Branka Djordjevic, Goran Marjanovic, Maja Milojkovic (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11676128.txt.
Description
Milenkovic and co-authors measure a protein called renalase in people with chronic myeloid leukemia. The cancer's inflamed setting may be one reason standard drugs fail to control it fully. Renalase calms inflammation and protects cells from death. It appears in many tissues, including tumors. The team compared blood levels in new patients, patients in remission on therapy, and healthy people.
New, untreated patients had far lower renalase than every other group. Levels in treated patients sat closer to normal. The drugs in use were imatinib and nilotinib, both standard for this leukemia. The shift hints that therapy partly restores the protein's balance. The authors see renalase as a marker worth tracking.
Catalog record
| CREATOR | Jelena Milenkovic, Dijana Stojanovic, Sanja Velickovic, Branka Djordjevic, Goran Marjanovic, Maja Milojkovic |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |